2013, Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events, NEJM
2018, Effect of Aspirin in elderly at moderate CVD risk | LANCET
2018, Effect of Aspirin on CV Events and Bleeding in the Healthy Elderly | NEJM
Let’s talk methodology… In this randomized, open-label, non-inferiority trial, the authors analyze a primary composite outcome that includes recurrent VTE and major bleeding in cancer patients taking edoxaban, a factor X inhibitor developed by the study sponsor, Daiichi-Sankyo. They conclude that when compared with LMWH, edoxaban is non-inferior for the aforementioned composite outcome. Because composites..